{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:49:57Z","timestamp":1791946197797,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL007088"],"award-info":[{"award-number":["T32HL007088"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL007088"],"award-info":[{"award-number":["T32HL007088"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL007088"],"award-info":[{"award-number":["T32HL007088"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K08HL106576"],"award-info":[{"award-number":["K08HL106576"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL134952"],"award-info":[{"award-number":["R01HL134952"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007427","name":"MPN Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007427","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA91842"],"award-info":[{"award-number":["P30CA91842"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Damon Runyon Cancer Foundation Doris Duke Charitable Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1038\/s41375-019-0379-y","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T05:03:53Z","timestamp":1549256633000},"page":"1978-1995","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":149,"title":["Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF\u03baB signaling"],"prefix":"10.1038","volume":"33","author":[{"given":"Daniel A. C.","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathrine A.","family":"Miner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth K.","family":"Engle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengrui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor B.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie J.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga N.","family":"Malkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-5400","authenticated-orcid":false,"given":"Stephen T.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"key":"379_CR1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","volume":"6","author":"S Elf","year":"2016","unstructured":"Elf S, Abdelfattah NS, Chen E, Perales-Paton J, Rosen EA, Ko A, et al. Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov. 2016;6:368\u201381.","journal-title":"Cancer Discov"},{"key":"379_CR2","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","volume":"116","author":"ST Oh","year":"2010","unstructured":"Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010;116:988\u201392.","journal-title":"Blood"},{"key":"379_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129:667\u201379.","journal-title":"Blood"},{"key":"379_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.beha.2014.07.008","volume":"27","author":"A Zhou","year":"2014","unstructured":"Zhou A, Oh ST. Prognostication in MF: from CBC to cytogenetics to molecular markers. Best Pract Res Clin Haematol. 2014;27:155\u201364.","journal-title":"Best Pract Res Clin Haematol"},{"key":"379_CR5","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/leu.2014.3","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28:1472\u20137.","journal-title":"Leukemia"},{"key":"379_CR6","doi-asserted-by":"publisher","first-page":"1179545X1769523","DOI":"10.1177\/1179545X17695233","volume":"10","author":"A Iurlo","year":"2017","unstructured":"Iurlo A, Cattaneo D. Treatment of myelofibrosis: old and new strategies. Clin Med Insights Blood Disord. 2017;10:1179545X17695233.","journal-title":"Clin Med Insights Blood Disord"},{"key":"379_CR7","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1182\/blood-2002-04-1133","volume":"100","author":"H Chagraoui","year":"2002","unstructured":"Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495\u2013503.","journal-title":"Blood"},{"key":"379_CR8","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29:1356\u201363.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"379_CR9","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","volume":"118","author":"AG Fleischman","year":"2011","unstructured":"Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, et al. TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011;118:6392\u20138.","journal-title":"Blood"},{"key":"379_CR10","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1038\/leu.2016.377","volume":"31","author":"DAC Fisher","year":"2017","unstructured":"Fisher DAC, Malkova O, Engle EK, Miner CA, Fulbright MC, Behbehani GK, et al. Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia. 2017;31:1962\u201374.","journal-title":"Leukemia"},{"key":"379_CR11","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1182\/blood-2016-11-731604","volume":"129","author":"F Cervantes","year":"2017","unstructured":"Cervantes F, Pereira A. Does ruxolitinib prolong the survival of patients with myelofibrosis? Blood. 2017;129:832\u20137.","journal-title":"Blood"},{"key":"379_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10:156.","journal-title":"J Hematol Oncol"},{"key":"379_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10:55.","journal-title":"J Hematol Oncol"},{"key":"379_CR14","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","volume":"126","author":"M Deininger","year":"2015","unstructured":"Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood. 2015;126:1551\u20134.","journal-title":"Blood"},{"key":"379_CR15","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117\u201327.","journal-title":"N Engl J Med"},{"key":"379_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1126\/science.1198704","volume":"332","author":"SC Bendall","year":"2011","unstructured":"Bendall SC, Simonds EF, Qiu P, Amir el AD, Krutzik PO, Finck R, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science. 2011;332:687\u201396.","journal-title":"Science"},{"key":"379_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2010.07.002","volume":"361","author":"O Ornatsky","year":"2010","unstructured":"Ornatsky O, Bandura D, Baranov V, Nitz M, Winnik MA, Tanner S. Highly multiparametric analysis by mass cytometry. J Immunol Methods. 2010;361:1\u201320.","journal-title":"J Immunol Methods"},{"key":"379_CR18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nbt.2594","volume":"31","author":"AD Amir el","year":"2013","unstructured":"Amir el AD, Davis KL, Tadmor MD, Simonds EF, Levine JH, Bendall SC, et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol. 2013;31:545\u201352.","journal-title":"Nat Biotechnol"},{"key":"379_CR19","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/nbt.1991","volume":"29","author":"P Qiu","year":"2011","unstructured":"Qiu P, Simonds EF, Bendall SC, Gibbs KD Jr., Bruggner RV, et al. Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol. 2011;29:886\u201391.","journal-title":"Nat Biotechnol"},{"key":"379_CR20","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1182\/blood-2013-12-544197","volume":"124","author":"R Norfo","year":"2014","unstructured":"Norfo R, Zini R, Pennucci V, Bianchi E, Salati S, Guglielmelli P, et al. miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155\/JARID2 axis in abnormal megakaryopoiesis. Blood. 2014;124:e21\u201332.","journal-title":"Blood"},{"key":"379_CR21","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1084\/jem.20110752","volume":"208","author":"CJ Pronk","year":"2011","unstructured":"Pronk CJ, Veiby OP, Bryder D, Jacobsen SE. Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors. J Exp Med. 2011;208:1563\u201370.","journal-title":"J Exp Med"},{"key":"379_CR22","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1172\/JCI68101","volume":"124","author":"Y Kagoya","year":"2014","unstructured":"Kagoya Y, Yoshimi A, Kataoka K, Nakagawa M, Kumano K, Arai S, et al. Positive feedback between NF-kappaB and TNF-alpha promotes leukemia-initiating cell capacity. J Clin Invest. 2014;124:528\u201342.","journal-title":"J Clin Invest"},{"key":"379_CR23","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1084\/jem.20130990","volume":"211","author":"A Volk","year":"2014","unstructured":"Volk A, Li J, Xin J, You D, Zhang J, Liu X, et al. Co-inhibition of NF-kappaB and JNK is synergistic in TNF-expressing human AML. J Exp Med. 2014;211:1093\u2013108.","journal-title":"J Exp Med"},{"key":"379_CR24","doi-asserted-by":"publisher","first-page":"e00537","DOI":"10.7554\/eLife.00537","volume":"2","author":"JL Zhao","year":"2013","unstructured":"Zhao JL, Rao DS, O\u2019Connell RM, Garcia-Flores Y, Baltimore D. MicroRNA-146a acts as a guardian of the quality and longevity of hematopoietic stem cells in mice. eLife. 2013;2:e00537.","journal-title":"eLife"},{"key":"379_CR25","doi-asserted-by":"publisher","unstructured":"Lin D, Gupta S, Maecker HT. Intracellular Cytokine Staining on PBMCs Using CyTOF MassCytometry. Bio Protoc. 2015; 5.\u00a0pii: e1370. \n                    https:\/\/doi.org\/10.21769\/BioProtoc.1370\n                    \n                  .","DOI":"10.21769\/BioProtoc.1370"},{"key":"379_CR26","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jaut.2017.03.010","volume":"81","author":"W.E. O'Gorman","year":"2017","unstructured":"O\u2019Gorman WE, Kong DS, Balboni IM, Rudra P, Bolen CR, Ghosh D, et al. Mass cytometry identifies a distinct monocyte cytokine signature shared by clinically heterogeneous pediatric SLE patients. J Autoimmun. 2017. pii: S0896-8411(16)30412-7. \n                    https:\/\/doi.org\/10.1016\/j.jaut.2017.03.010\n                    \n                  . [Epub ahead of print].","journal-title":"Journal of Autoimmunity"},{"key":"379_CR27","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nprot.2015.020","volume":"10","author":"ER Zunder","year":"2015","unstructured":"Zunder ER, Finck R, Behbehani GK, Amir el AD, Krishnaswamy S, Gonzalez VD, et al. Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. Nat Protoc. 2015;10:316\u201333.","journal-title":"Nat Protoc"},{"key":"379_CR28","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1182\/blood-2016-09-741611","volume":"129","author":"K Miyawaki","year":"2017","unstructured":"Miyawaki K, Iwasaki H, Jiromaru T, Kusumoto H, Yurino A, Sugio T, et al. Identification of unipotent megakaryocyte progenitors in human hematopoiesis. Blood. 2017;129:3332\u201343.","journal-title":"Blood"},{"key":"379_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0939-7","volume":"17","author":"B Psaila","year":"2016","unstructured":"Psaila B, Barkas N, Iskander D, Roy A, Anderson S, Ashley N, et al. Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways. Genome Biol. 2016;17:83.\u00a0\n                    https:\/\/doi.org\/10.1186\/s13059-016-0939-7\n                    \n                  .","journal-title":"Genome Biol"},{"key":"379_CR30","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1182\/blood-2010-12-326355","volume":"118","author":"KL Wong","year":"2011","unstructured":"Wong KL, Tai JJ, Wong WC, Han H, Sem X, Yeap WH, et al. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood. 2011;118:e16\u201331.","journal-title":"Blood"},{"key":"379_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/MOH.0000000000000122","volume":"22","author":"GS Hobbs","year":"2015","unstructured":"Hobbs GS, Rampal RK. Clinical and molecular genetic characterization of myelofibrosis. Curr Opin Hematol. 2015;22:177\u201383.","journal-title":"Curr Opin Hematol"},{"key":"379_CR32","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3389\/fimmu.2016.00390","volume":"7","author":"DA Monlish","year":"2016","unstructured":"Monlish DA, Bhatt ST, Schuettpelz LG. The role of toll-like receptors in hematopoietic malignancies. Front Immunol. 2016;7:390.","journal-title":"Front Immunol"},{"key":"379_CR33","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/leu.2013.180","volume":"27","author":"Y Wei","year":"2013","unstructured":"Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, et al. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia. 2013;27:1832\u201340.","journal-title":"Leukemia"},{"key":"379_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.exphem.2015.12.004","volume":"44","author":"L Petit Cocault","year":"2016","unstructured":"Petit Cocault L, Fleury M, Clay D, Larghero J, Vanneaux V, Souyri M. Monoclonal antibody 1.6.1 against human MPL receptor allows HSC enrichment of CB and BM CD34(+)CD38(\u2212) populations. Exp Hematol. 2016;44:297\u2013302 e1.","journal-title":"Exp Hematol"},{"key":"379_CR35","doi-asserted-by":"publisher","first-page":"5411","DOI":"10.1172\/JCI75661","volume":"124","author":"TU Barbie","year":"2014","unstructured":"Barbie TU, Alexe G, Aref AR, Li S, Zhu Z, Zhang X, et al. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest. 2014;124:5411\u201323.","journal-title":"J Clin Invest"},{"key":"379_CR36","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1158\/2326-6066.CIR-15-0235","volume":"4","author":"S Yang","year":"2016","unstructured":"Yang S, Imamura Y, Jenkins RW, Canadas I, Kitajima S, Aref A, et al. Autophagy inhibition dysregulates TBK1 signaling and promotes pancreatic inflammation. Cancer Immunol Res. 2016;4:520\u201330.","journal-title":"Cancer Immunol Res"},{"key":"379_CR37","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1158\/2159-8290.CD-13-0646","volume":"4","author":"Z Zhu","year":"2014","unstructured":"Zhu Z, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang S, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014;4:452\u201365.","journal-title":"Cancer Discov"},{"key":"379_CR38","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2009.50","volume":"23","author":"A Pardanani","year":"2009","unstructured":"Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1\/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia. 2009;23:1441\u20135.","journal-title":"Leukemia"},{"key":"379_CR39","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3324\/haematol.2016.151126","volume":"102","author":"JO Mascarenhas","year":"2017","unstructured":"Mascarenhas JO, Talpaz M, Gupta V, Foltz LM, Savona MR, Paquette R, et al. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. 2017;102:327\u201335.","journal-title":"Haematologica"},{"key":"379_CR40","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1080\/14656566.2017.1404574","volume":"18","author":"M Griesshammer","year":"2017","unstructured":"Griesshammer M, Sadjadian P. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium. Expert Opin Pharmacother. 2017;18:1929\u201338.","journal-title":"Expert Opin Pharmacother"},{"key":"379_CR41","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1007\/s10495-008-0243-4","volume":"13","author":"J Grosjean-Raillard","year":"2008","unstructured":"Grosjean-Raillard J, Ades L, Boehrer S, Tailler M, Fabre C, Braun T, et al. Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Apoptosis: Int J Program Cell death. 2008;13:1148\u201361.","journal-title":"Apoptosis: Int J Program Cell death"},{"key":"379_CR42","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/onc.2008.457","volume":"28","author":"J Grosjean-Raillard","year":"2009","unstructured":"Grosjean-Raillard J, Tailler M, Ades L, Perfettini JL, Fabre C, Braun T, et al. ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene. 2009;28:1099\u2013109.","journal-title":"Oncogene"},{"key":"379_CR43","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1182\/blood.V98.8.2301","volume":"98","author":"ML Guzman","year":"2001","unstructured":"Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301\u20137.","journal-title":"Blood"},{"key":"379_CR44","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1182\/blood-2009-11-254862","volume":"115","author":"RT Swords","year":"2010","unstructured":"Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood. 2010;115:3796\u2013800.","journal-title":"Blood"},{"key":"379_CR45","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1038\/leu.2015.106","volume":"29","author":"J Khalife","year":"2015","unstructured":"Khalife J, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J, et al. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia. 2015;29:1981\u201392.","journal-title":"Leukemia"},{"key":"379_CR46","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1182\/blood-2014-05-574582","volume":"124","author":"MR Burgess","year":"2014","unstructured":"Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, et al. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood. 2014;124:3947\u201355.","journal-title":"Blood"},{"key":"379_CR47","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1021\/ml2001455","volume":"2","author":"JP Duffy","year":"2011","unstructured":"Duffy JP, Harrington EM, Salituro FG, Cochran JE, Green J, Gao H, et al. The discovery of VX-745: a novel and selective p38alpha kinase inhibitor. ACS Med Chem Lett. 2011;2:758\u201363.","journal-title":"ACS Med Chem Lett"},{"key":"379_CR48","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1021\/jm060199b","volume":"49","author":"BG Szczepankiewicz","year":"2006","unstructured":"Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, et al. Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006;49:3563\u201380.","journal-title":"J Med Chem"},{"key":"379_CR49","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.chembiol.2011.11.010","volume":"19","author":"T Zhang","year":"2012","unstructured":"Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T, et al. Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012;19:140\u201354.","journal-title":"Chem Biol"},{"key":"379_CR50","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","volume":"5","author":"M Kleppe","year":"2015","unstructured":"Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015;5:316\u201331.","journal-title":"Cancer Discov"},{"key":"379_CR51","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1182\/blood-2014-03-559641","volume":"124","author":"K Mizrahi","year":"2014","unstructured":"Mizrahi K, Askenasy N. Physiological functions of TNF family receptor\/ligand interactions in hematopoiesis and transplantation. Blood. 2014;124:176\u201383.","journal-title":"Blood"},{"issue":"1","key":"379_CR52","doi-asserted-by":"publisher","first-page":"29-43.e7","DOI":"10.1016\/j.ccell.2017.11.009","volume":"33","author":"Maria Kleppe","year":"2018","unstructured":"Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell. 2018;33:29\u201343.e7. \n                    https:\/\/doi.org\/10.1016\/j.ccell.2017.11.009\n                    \n                  . Epub 2017 Dec 14.","journal-title":"Cancer Cell"},{"key":"379_CR53","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.stem.2017.08.011","volume":"21","author":"M Kleppe","year":"2017","unstructured":"Kleppe M, Spitzer MH, Li S, Hill CE, Dong L, Papalexi E, et al. Jak1 Integrates cytokine sensing to regulate hematopoietic stem cell function and stress hematopoiesis. Cell Stem Cell. 2017;21:489\u2013501 e7.","journal-title":"Cell Stem Cell"},{"key":"379_CR54","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ccr.2010.10.013","volume":"18","author":"E Chen","year":"2010","unstructured":"Chen E, Beer PA, Godfrey AL, Ortmann CA, Li J, Costa-Pereira AP, et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell. 2010;18:524\u201335.","journal-title":"Cancer Cell"},{"key":"379_CR55","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/ijms19103198","volume":"19","author":"D Staudt","year":"2018","unstructured":"Staudt D, Murray HC, McLachlan T, Alvaro F, Enjeti AK, Verrills NM, et al. Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia: the path to least resistance. Int J Mol Sci. 2018;19:10.","journal-title":"Int J Mol Sci"},{"key":"379_CR56","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3324\/haematol.2016.148924","volume":"102","author":"V Gupta","year":"2017","unstructured":"Gupta V, Mesa RA, Deininger MW, Rivera CE, Sirhan S, Brachmann CB, et al. A phase 1\/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica. 2017;102:94\u2013102.","journal-title":"Haematologica"},{"key":"379_CR57","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/leu.2013.71","volume":"27","author":"A Pardanani","year":"2013","unstructured":"Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013;27:1322\u20137.","journal-title":"Leukemia"},{"key":"379_CR58","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","volume":"29","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29:789\u201396.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"11","key":"379_CR59","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1038\/s41375-018-0131-z","volume":"32","author":"William L. Heaton","year":"2018","unstructured":"Heaton WL, Senina AV, Pomicter AD, Salama ME, Clair PM, Yan D, et al. Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion. Leukemia. 2018; \n                    https:\/\/doi.org\/10.1038\/s41375-018-0131-z\n                    \n                  . [Epub ahead of print].","journal-title":"Leukemia"},{"key":"379_CR60","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1182\/blood-2015-01-621631","volume":"125","author":"C Schinke","year":"2015","unstructured":"Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreyro L, et al. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood. 2015;125:3144\u201352.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0379-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0379-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0379-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:36:43Z","timestamp":1684604203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0379-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,4]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["379"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0379-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,4]]},"assertion":[{"value":"25 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}